Business
CSL profits boom 45pc as flu business soars – The Australian Financial Review
The blood products giant notched up its fastest profit and revenue growth in recent years despite a uniquely challenging first half.
Sales of CSLs Hizentra product grew strongly, up 19 per cent, reflecting the benefits of home administration and the continued strong uptake for the treatment of the debilitating neurological disorder CIDP (chronic inflammatory demyelinating polyneuropathy).
The company declared a dividend of $US1.04 per share, up 9 per cent.
Guidance maintained
Despite the strong growth in the first half, the company maintained its full-year guidance of net profit of $US2.17 billion to $US2.265 billion at constant…
-
Noosa News22 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
General20 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
Noosa News22 hours agoAustralian NFL player Laki Tasi comes home to convince kids to switch codes
-
Business22 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000